Bio Blast Pharma Ltd (ORPN)

0.01 0.58
NASDAQ : Health Care
Prev Close 1.73
Open 1.74
Day Low/High 1.61 / 1.75
52 Wk Low/High 1.53 / 7.95
Volume 140.63K
Avg Volume 118.90K
Exchange NASDAQ
Shares Outstanding 14.23M
Market Cap 24.76M
EPS -1.10
P/E Ratio 1.61
Div & Yield N.A. (N.A)

7 Stocks Under $10 to Trade for Big Profits

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

BioBlast Pharma To Present Final HOPEMD Phase 2 Clinical Study Results Of Trehalose In Oculopharyngeal Muscular Dystrophy At The American Academy Of Neurology (AAN) 2016 Annual Meeting

Final Results of 24-Week Open-Label Phase 2 Trial Will be Presented by Professor Zohar Argov, MD, Senior Medical Advisor to BioBlast Pharma

5 Stocks Under $10 Set to Soar

These under-$10 stocks are within range of triggering big breakouts.

BioBlast Pharma Enhances Leadership Team

Appoints Industry Veteran, Robert W. Cook, as Chief Financial Officer

BioBlast Scant Data Links Drug to Improved Swallowing in Patients

BioBlast paints a very optimistic picture of Cabaletta's potential as an effective treatment for OPMD, but the data announced Tuesday are scant, cherry-picked and hardly conclusive.

BioBlast Pharma Augments Leadership Team

Appoints Former Aptalis and Novartis Executive, Theresa M. Stevens, as Chief Corporate Development Officer

BioBlast Pharma Augments Leadership Team And Establishes U.S. Headquarters In New Haven, Connecticut

Appoints Former NPS and ViroPharma Executive, Paul Firuta as Chief Commercial Officer

Market News: Bio Blast Pharma, Micron Technology, Nike

The stock markets fluctuated and ended the trading session lower except the Dow Jones Industrial Average (DJIA), up 0.32%. Sign up for our free newsletter Companies in the semiconductor industry expe...

BioBlast Announces The Start Of A Phase 3 Study For Cabaletta In Oculopharyngeal Muscular Dystrophy (OPMD)

New Pivotal Study Reflects Positive Signals Reported From the Current HOPEMD Study, Which Will Be Closed Out at 25 Patients